The ARCUS genome-editing technology is used in the anti-CD19 allogenic CAR-T product PBCAR0191, currently being tested in a Phase I/II study for R/R non-Hodgkin’s lymphoma (R/R NHL) and B-ALL (NCT03666000). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.